NicVAX/Placebo as an Aid for Smoking Cessation
Completed
The purpose of this study is to evaluate NicVAX as an aid to smoking cessation for long term abstinence.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2012
Locations: NicVAX Investigator, Omaha, Nebraska
Conditions: Smoking Cessation, Smoking, Tobacco Cessation
Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers
Completed
This Phase 2(a) clinical trial is designed as a dose-blinded, block-randomized, multi-center study to select a dosage and schedule of rF1V vaccine for further studies based on the immune response up to Day 210. Additional immunogenicity and safety/reactogenicity data will be collected through Day 540. Selection of dosage and schedule will be based on GMCs and seroconversion rates for anti-F1, anti-V and anti-rF1V antibody titers. Approximately 400 healthy adult volunteers will be enrolled (100 p... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Meridian clinical Research, LLC, Omaha, Nebraska
Conditions: Healthy Volunteers
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
Completed
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/10/2011
Locations: Bergan Mercy Medical Center, Omaha, Nebraska
Conditions: Unspecified Adult Solid Tumor, Protocol Specific